EU REP Symbol Transition Under MDR & IVDR: What Medical Device Manufacturers Must Do Before The 2031 Transition Deadline

Understanding Commission Implementing Decision (EU) 2026/1313, EN ISO 15223-1:2021/A1:2025 Harmonization, the Shift from EC REP to EU REP, and Best Practices for EU Medical Device Labelling Compliance

The European Commission has taken another important step toward strengthening consistency within the European medical device regulatory framework through the publication of Commission Implementing Decision (EU) 2026/1313.

Published in the Official Journal of the European Union, the Decision harmonizes EN ISO 15223-1:2021/A1:2025 under both the Medical Devices Regulation (EU) 2017/745 (MDR) and the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR).

Among the most significant changes introduced is the official replacement of the long-established "EC REP" designation with "EU REP" for the Authorized Representative symbol.

Although this may appear to be a relatively small labelling update, it reflects the European Union's broader objective of aligning harmonized standards with the current regulatory framework established under MDR and IVDR.

To minimize operational disruption, the European Commission has introduced a five-year coexistence period, allowing manufacturers sufficient time to implement changes through planned label updates and product lifecycle management.

Manufacturers that begin planning early will be better positioned to maintain regulatory compliance while avoiding unnecessary relabeling costs and supply chain disruptions.

Without early preparation, companies may encounter:

• Regulatory non-compliance 
• Delays in product updates 
• Increased labelling revision costs 
• Packaging redesign challenges 
• Supplier coordination issues 
• Technical documentation updates
• Delayed product releases 
• Additional notified body questions 
• Quality system revisions 
• Increased operational complexity 

As implementation activities begin across the industry, proactive planning will become increasingly important.

Executive Overview

Commission Implementing Decision (EU) 2026/1313 formally harmonizes the latest amendment to EN ISO 15223-1, introducing updated medical device symbols that better reflect today's European regulatory environment.

Rather than requiring immediate relabeling, the Commission has adopted a practical transition approach that supports business continuity while encouraging gradual implementation.

A future-ready labelling program should be:

• MDR compliant 
• IVDR compliant 
• Harmonized standard aligned 
• Technically documented 
• Quality system integrated 
• Change-control managed 
• Supply chain coordinated 
• Inspection ready 

Organizations that integrate these changes into routine product maintenance activities can significantly reduce future compliance risks.

Why This Harmonization Matters

Medical device labels represent one of the most visible aspects of regulatory compliance.

The harmonization of EN ISO 15223-1:2021/A1:2025 ensures that symbol terminology reflects the legal framework introduced by MDR and IVDR rather than previous Medical Device Directives.

This update improves:

• Regulatory consistency 
• International clarity 
• Standard harmonization 
• Labelling accuracy 
• Market confidence 
• Compliance transparency 

While the practical impact on patients remains minimal, the regulatory significance for manufacturers is substantial.

Key Drivers Behind the EU REP Transition

Medical device labelling continues evolving alongside the broader European regulatory framework.

Top 5 Compliance Priorities Following Decision (EU) 2026/1313

1. Assess Existing Product Labels

Manufacturers should determine where the "EC REP" symbol currently appears.

Areas requiring review include:

• Device labels 
• Packaging artwork 
• Instructions for Use (IFUs) 
• Electronic labelling 
• Product catalogues 
• Technical documentation 

Potential Impact

A complete label inventory simplifies future implementation.

2. Review Change Management Procedures

Organizations should evaluate how this update fits within existing quality management systems.

Review should include:

• Design control 
• Change control 
• Regulatory assessment 
• Risk evaluation 
• Document control 
• Product lifecycle planning 

Integrating symbol updates into planned revisions reduces unnecessary costs.

3. Coordinate Global Packaging Updates

Many manufacturers use unified packaging across multiple markets.

Companies should evaluate:

• Global artwork strategies 
• Country-specific labels 
• Regional regulatory requirements 
• Translation impacts 
• Printing schedules 
• Packaging inventories 

Coordinated planning helps avoid duplicate revisions.

4. Update Technical Documentation

Although the symbol change is relatively straightforward, supporting documentation may require updates.

Documentation may include:

• Device descriptions 
• Label specifications 
• IFUs 
• Technical files 
• Design history documentation 
• Declaration of Conformity references 

Maintaining complete documentation supports future inspections.

5. Prepare for Future MDCG Guidance

The Medical Device Coordination Group (MDCG) is expected to provide further clarification as revisions to MDCG 2021-5 progress.

Manufacturers should monitor:

• MDCG guidance updates 
• European Commission publications 
• Harmonized standards revisions 
• Notified Body expectations 
• Industry best practices 

Ongoing regulatory intelligence supports continuous compliance.

The Growing Importance of Medical Device Labelling Governance

Medical device labelling is becoming increasingly interconnected with:

• Digital documentation 
• UDI implementation 
• Regulatory databases 
• Global product lifecycle management 
• Electronic IFUs 
• Quality management systems 

Strong labelling governance reduces long-term compliance risks.

Practical Benefits of Early Preparation

Organizations that begin planning now can integrate changes into existing update cycles rather than initiating standalone projects.

Important Compliance Considerations

Successful implementation should include:

• Label inventory reviews 
• Packaging artwork assessments 
• IFU evaluations 
• Technical documentation updates
• Change control planning 
• Supplier coordination 
• Regulatory impact assessments 
• Quality management integration 
• Ongoing regulatory monitoring 

Implementation should be managed strategically rather than through last-minute revisions.

Best Practices for Compliance Excellence

Conduct Comprehensive Labelling Reviews

Manufacturers should evaluate:

• Product labels 
• Packaging 
• IFUs 
• Electronic documentation 
• Regulatory submissions 
• Artwork libraries 

Strengthening Cross-Functional Collaboration

Successful implementation requires coordination among:

• Regulatory Affairs 
• Quality Assurance 
• Packaging Engineering 
• Product Development 
• Supply Chain 
• Manufacturing 
• Marketing 
• Document Control 

Improve Change Planning

Organizations should be established:

• Transition timelines 
• Risk assessments 
• Product prioritization 
• Inventory management 
• Implementation milestones 

Monitor Regulatory Developments

Companies should continue monitoring:

• European Commission publications 
• MDCG guidance 
• Harmonized standards 
• Industry associations 
• Notified Body communications 

Emerging Trends in Medical Device Labelling

Labelling continues evolving as a strategic component of regulatory compliance.

Why Early Planning Creates Competitive Advantage

Forward-looking manufacturers increasingly differentiate themselves through:

• Regulatory readiness 
• Efficient management 
• Robust quality systems 
• Global labelling consistency 
• Technical documentation excellence 
• Proactive regulatory intelligence 

Organizations that prepare early can:

• Reduce implementation costs 
• Avoid last-minute product updates 
• Simplify regulatory inspections
• Strengthening quality systems 
• Improve operational efficiency 
• Maintain uninterrupted EU market access 

Compliance planning increasingly supports both regulatory success and operational excellence.

How Maven Supports Manufacturers

Our Expertise Includes

• MDR regulatory consulting 
• IVDR compliance support 
• Medical device labelling reviews 
• Harmonized standards implementation 
• Technical documentation support 
• Change management consulting 
• IFU compliance assessments 
• Packaging artwork reviews 
• Regulatory intelligence 
• Global market access consulting 

Why Manufacturers Choose Maven

• Deep European Regulatory Expertise 
• Medical device compliance specialists 
• Practical implementation strategies 
• Risk-based regulatory approach 
• Global market knowledge 
• End-to-end compliance support 
• Scalable regulatory solutions 

Conclusion

The publication of Commission Implementing Decision (EU) 2026/1313 represents another important milestone in the ongoing evolution of the European medical device regulatory framework.

Although the transition from "EC REP" to "EU REP" may appear modest, it reinforces regulatory consistency between harmonized standards and MDR/IVDR requirements.

The five-year coexistence period provides manufacturers with valuable flexibility to implement changes efficiently through planned product lifecycle updates rather than costly standalone relabeling projects.

Organizations that proactively review:

• Product labelling 
• Packaging artwork 
• Instructions for Use 
• Technical documentation 
• Change management processes 
• Regulatory planning 
• Quality systems 

will be well positioned to maintain compliance while minimizing operational disruption.

Ultimately, successful implementation extends beyond updating a symbol to demonstrate a manufacturer's commitment to regulatory excellence, quality, and long-term compliance within the evolving European medical device landscape.

Frequently Asked Questions

1. What is Commission Implementing Decision (EU) 2026/1313?

It is a European Commission Implementing Decision that harmonizes EN ISO 15223-1:2021/A1:2025 under both MDR and IVDR, updating medical device symbol requirements, including the transition from EC REP to EU REP.

2. What changes are the differences from EC REP to EU REP?

The harmonized standard replaces the historical EC REP terminology with EU REP for the Authorized Representative symbol to align with the current European Union regulatory framework.

3. Is immediate relabeling required?

No. The European Commission has established a five-year coexistence period, allowing manufacturers to transition during planned product and packaging updates.

4. Which products are affected?

The harmonized standard applies to medical devices and in vitro diagnostic medical devices placed on the EU market under MDR and IVDR.

5. What should manufacturers review?

Manufacturers should assess labels, IFUs, packaging artwork, technical documentation, quality management procedures, and change control processes.

6. Will additional guidance be published?

Yes. Further clarification is expected as revisions to MDCG 2021-5 progress.

7. Why is this update important?

It improves consistency between harmonized standards and the current EU regulatory framework while supporting long-term compliance.

8. How can Maven help?

We support manufacturers with MDR and IVDR compliance, harmonized standards implementation, labelling reviews, technical documentation, regulatory intelligence, and strategic regulatory consulting.